No Clinically Significant Drug Interaction Between Levetiracetam and Acenocoumarol
Based on FDA-approved drug labeling, levetiracetam does not interact with warfarin (and by extension acenocoumarol), as it does not affect prothrombin time or the pharmacokinetics of warfarin. 1
Mechanism and Evidence
Levetiracetam has a favorable drug interaction profile due to its unique pharmacokinetic properties:
No cytochrome P450 involvement: Levetiracetam and its metabolites are neither inhibitors nor substrates for hepatic CYP450 enzymes, epoxide hydrolase, or UDP-glucuronidation enzymes 1
Minimal protein binding: Circulates <10% bound to plasma proteins, eliminating competition for protein binding sites 1
Direct warfarin study: Clinical pharmacokinetic studies demonstrated that levetiracetam 1000 mg twice daily did not influence the pharmacokinetics of R or S warfarin, and prothrombin time remained unaffected 1
Clinical Application
Since acenocoumarol is a vitamin K antagonist with similar mechanisms to warfarin (both inhibit synthesis of factors II, VII, IX, X), the lack of interaction with warfarin directly translates to acenocoumarol 2, 3. Acenocoumarol has a shorter half-life (9 hours) compared to warfarin (42 hours), but this does not create additional interaction risk with levetiracetam 2.
You can safely co-prescribe these medications without dose adjustment of either agent. Standard INR monitoring for acenocoumarol should continue per usual protocols, but no additional monitoring is required due to levetiracetam co-administration.
Important Caveat
While the FDA labeling and pharmacokinetic data are reassuring, one recent pharmacovigilance study 4 reported signals for ischemic stroke with levetiracetam and direct oral anticoagulants (DOACs), suggesting possible P-glycoprotein induction. However, this finding applies to DOACs (apixaban, rivaroxaban, dabigatran, edoxaban), not vitamin K antagonists like acenocoumarol, which are not P-glycoprotein substrates. The mechanism of action and elimination pathways differ fundamentally between DOACs and acenocoumarol.